Repurposing of Linagliptin and Similar FDA Approved Drugs as Antidiabetic Agents

The study addresses the global challenge of diabetes mellitus by exploring drug repurposing as a solution to the difficulties in discovering new antidiabetic drugs. Using a computational approach, researchers identified 26 FDA-approved drugs with structural similarities to the DPP-IV inhibitor Linagliptin. Further filtering and molecular docking studies revealed that pranlukast and mirabegron exhibited strong binding interactions with DPP-IV, with dock scores of -13.81 and -13.06, respectively, suggesting their potential as antidiabetic agents.